SynthesisCancer medicine2026

Pharmacoeconomic Analysis of Osimertinib Compared to Earlier-Generation EGFR Inhibitors in EGFR-Mutated NSCLC: A Systematic Review.

Nicola Perrotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.